Straumann Holding AG

LSE:0QMV Stock Report

Market Cap: CHF 18.2b

Straumann Holding Valuation

Is 0QMV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QMV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QMV (CHF114.68) is trading above our estimate of fair value (CHF110.78)

Significantly Below Fair Value: 0QMV is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QMV?

Key metric: As 0QMV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QMV. This is calculated by dividing 0QMV's market cap by their current earnings.
What is 0QMV's PE Ratio?
PE Ratio63.1x
EarningsCHF 287.88m
Market CapCHF 18.15b

Price to Earnings Ratio vs Peers

How does 0QMV's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QMV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.7x
SN. Smith & Nephew
35.7x22.5%UK£8.6b
NIOX NIOX Group
22.7x15.8%UK£249.9m
CTEC ConvaTec Group
40.1x20.4%UK£4.8b
EKF EKF Diagnostics Holdings
24.4xn/aUK£116.6m
0QMV Straumann Holding
63.1x21.1%CHF 18.2b

Price-To-Earnings vs Peers: 0QMV is expensive based on its Price-To-Earnings Ratio (63.1x) compared to the peer average (30.7x).

Price to Earnings Ratio vs Industry

How does 0QMV's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0QMV 63.1xIndustry Avg. 29.6xNo. of Companies8PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QMV is expensive based on its Price-To-Earnings Ratio (63.1x) compared to the European Medical Equipment industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 0QMV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QMV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio63.1x
Fair PE Ratio46.8x

Price-To-Earnings vs Fair Ratio: 0QMV is expensive based on its Price-To-Earnings Ratio (63.1x) compared to the estimated Fair Price-To-Earnings Ratio (46.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QMV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 114.68
CHF 131.89
+15.0%
16.9%CHF 175.00CHF 90.00n/a18
Nov ’25CHF 116.25
CHF 133.82
+15.1%
16.3%CHF 175.00CHF 90.00n/a17
Oct ’25CHF 139.12
CHF 137.06
-1.5%
16.4%CHF 175.00CHF 90.00n/a18
Sep ’25CHF 125.50
CHF 134.83
+7.4%
16.9%CHF 175.00CHF 90.00n/a18
Aug ’25CHF 113.45
CHF 134.33
+18.4%
18.1%CHF 175.00CHF 90.00n/a18
Jul ’25CHF 112.40
CHF 134.39
+19.6%
18.4%CHF 175.00CHF 90.00n/a18
Jun ’25CHF 117.30
CHF 135.94
+15.9%
18.2%CHF 175.00CHF 90.00n/a18
May ’25CHF 126.97
CHF 138.67
+9.2%
18.4%CHF 175.00CHF 90.00n/a18
Apr ’25CHF 144.02
CHF 142.32
-1.2%
18.4%CHF 175.00CHF 90.00n/a19
Mar ’25CHF 142.75
CHF 134.22
-6.0%
17.7%CHF 168.00CHF 90.00n/a18
Feb ’25CHF 138.96
CHF 128.22
-7.7%
16.1%CHF 153.00CHF 90.00n/a18
Jan ’25CHF 135.60
CHF 125.41
-7.5%
15.2%CHF 150.00CHF 90.00n/a17
Dec ’24CHF 119.46
CHF 124.47
+4.2%
14.8%CHF 150.00CHF 90.00n/a17
Nov ’24CHF 105.60
CHF 131.99
+25.0%
16.8%CHF 167.00CHF 90.00CHF 116.2517
Oct ’24CHF 117.20
CHF 135.38
+15.5%
18.0%CHF 167.00CHF 90.00CHF 139.1216
Sep ’24CHF 133.10
CHF 136.82
+2.8%
17.7%CHF 167.00CHF 90.00CHF 125.5017
Aug ’24CHF 143.93
CHF 134.47
-6.6%
20.4%CHF 165.00CHF 82.00CHF 113.4517
Jul ’24CHF 144.16
CHF 133.76
-7.2%
21.1%CHF 165.00CHF 82.00CHF 112.4017
Jun ’24CHF 134.89
CHF 131.88
-2.2%
22.3%CHF 165.00CHF 82.00CHF 117.3016
May ’24CHF 131.63
CHF 124.87
-5.1%
21.4%CHF 160.00CHF 82.00CHF 126.9715
Apr ’24CHF 136.02
CHF 124.53
-8.4%
21.8%CHF 160.00CHF 82.00CHF 144.0215
Mar ’24CHF 123.95
CHF 120.43
-2.8%
21.2%CHF 158.00CHF 80.00CHF 142.7514
Feb ’24CHF 121.05
CHF 116.21
-4.0%
20.4%CHF 150.00CHF 80.00CHF 138.9614
Jan ’24CHF 106.35
CHF 119.00
+11.9%
18.7%CHF 150.00CHF 88.00CHF 135.6013
Dec ’23CHF 108.65
CHF 122.08
+12.4%
17.9%CHF 153.00CHF 90.00CHF 119.4612
Nov ’23CHF 95.49
CHF 129.29
+35.4%
23.9%CHF 205.00CHF 90.00CHF 105.6013

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$403.49

7D

0.4%

1Y

-15.5%

Patterson Companies

US$1.9b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

0KGB

US$21.68

7D

7.0%

1Y

-14.5%

Kooth

UK£66.0m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.81

7D

11.0%

1Y

-38.2%